| Drug Name: | Sorafenib (284461-73-0) |
|---|---|
| PubChem ID: | 216239 |
| SMILES: | CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F |
| InchiKey: | MLDQJTXFUGDVEO-UHFFFAOYSA-N |
| Therapeutic Category: | Antineoplastic Agents, Enzyme Inhibitors, Protein Kinase Inhibitors |
| Molecular Weight (dalton) | : | 464.831 |
| LogP | : | 5.5497 |
| Ring Count | : | 3 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 92.35 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Warfarin (81-81-2) | Bleeding | Antagonistic | sorafenib inhibits the cytochrome P450 isoenzyme CYP2C9, the main isoenzyme involved in the metabolism of warfarin. | Fulminant Hepatitis and Fatal Toxic Epidermal Necrolysis (Lyell Disease) Coincident With Clarithromycin Administration in an Alcoholic Patient Receiving Disulfiram Therapy |
| Warfarin (81-81-2) | International Normalized Ratio Increased | Antagonistic | sorafenib inhibits the cytochrome P450 isoenzyme CYP2C9, the main isoenzyme involved in the metabolism of warfarin. | Pancytopenia and Colitis with Clostridium difficile in a Rheumatoid Arthritis Patient Taking Methotrexate, Antibiotics and Non-steroidal Anti-inflammatory Drugs |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category